Parabilis Medicines Inc.
Organization details
- Legal name
- Parabilis Medicines Inc.
- Former names
- FOG Pharmaceuticals, INC.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- PBLS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001657677
- EIN
- 47-4505725
Board of directors
-
Alan Sebulsky · DirectorSince 2026
- Since 2026
-
Barbara Weber · DirectorSince 2026
-
Craig Tendler · DirectorSince 2026
-
Edward M. Fitzgerald · DirectorSince 2026
- Since 2026
-
Krishna Yeshwant · DirectorSince 2026
-
Mathai Mammen · Director · President & CEOSince 2026
- Since 2026
- Since 2026
-
Richard Klausner · DirectorSince 2026
Chief executives
Board connections
9 of this board's directors also sit on 33 other boards. 32 are in the same sector.
-
Bicara Therapeutics Inc. Same sectorvia Jake Simson, Peter Kolchinsky and Rajeev M. Shah
-
Janux Therapeutics Inc. Same sectorvia Jake Simson, Peter Kolchinsky and Rajeev M. Shah
-
Septerna Inc. Same sectorvia Jake Simson, Peter Kolchinsky and Rajeev M. Shah
-
Tyra Biosciences Inc. Same sectorvia Jake Simson, Peter Kolchinsky and Rajeev M. Shah
-
ARS Pharmaceuticals Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Acrivon Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Acumen Pharmaceuticals Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Artiva Biotherapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Bambusa Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Black Diamond Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Climb Bio Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Evommune Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Freenome Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Hemab Therapeutics Holdings Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Jade Biosciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
LENZ Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Mineralys Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Nkarta Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
PepGen Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Revolution Medicines Inc. Same sectorvia Alexis Borisy and Barbara Weber
-
Sionna Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Solid Biosciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
SpyGlass Pharma Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Tango Therapeutics Inc. Same sectorvia Alexis Borisy and Barbara Weber
-
Vor Biopharma Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Wave Life Sciences Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
-
Werewolf Therapeutics Inc. Same sectorvia Peter Kolchinsky and Rajeev M. Shah
- via Mathai Mammen
-
Lyell Immunopharma Inc. Same sectorvia Richard Klausner
-
MeiraGTx Holdings plc Same sectorvia Alan Sebulsky
-
OPKO Health Inc. Same sectorvia Alexis Borisy
-
Relay Therapeutics Inc. Same sectorvia Alexis Borisy
-
TuHURA Biosciences Inc. Same sectorvia Craig Tendler
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $441,418,109
- 14 purchases by 4 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 22, 2026 | RA CAPITAL MANAGEMENT, L.P. Director, 10% owner | Open-market purchase | +47,250 | $29.77 | $1,406,633 |
| Jul 21, 2026 | RA CAPITAL MANAGEMENT, L.P. Director, 10% owner | Open-market purchase | +21,696 | $27.96 | $606,620 |
| Jul 21, 2026 | RA CAPITAL MANAGEMENT, L.P. Director, 10% owner | Open-market purchase | +6,504 | $29.17 | $189,722 |
| Jul 21, 2026 | RA CAPITAL MANAGEMENT, L.P. Director, 10% owner | Open-market purchase | +37,723 | $30.00 | $1,131,690 |
| Jul 20, 2026 | RA CAPITAL MANAGEMENT, L.P. Director, 10% owner | Open-market purchase | +98,433 | $27.13 | $2,670,487 |
| Jul 20, 2026 | RA CAPITAL MANAGEMENT, L.P. Director, 10% owner | Open-market purchase | +32,987 | $27.72 | $914,400 |
| Jun 15, 2026 | Alan Sebulsky Director | Open-market purchase | +5,000 | $26.00 | $130,000 |
| Jun 15, 2026 | Alan Sebulsky Director | Open-market purchase | +4,065 | $27.10 | $110,162 |
| Jun 12, 2026 | Alan Sebulsky Director | Open-market purchase | +8,435 | $27.67 | $233,396 |
| Jun 11, 2026 | Soleus Capital Group, LLC 10% owner | Open-market purchase | +375,000 | $20.00 | $7,500,000 |
| Jun 11, 2026 | RA Capital Nexus Fund III, L.P. Director | Derivative conversion | +6,556,740 | — | — |
| Jun 11, 2026 | Edward M. Fitzgerald Director | Derivative conversion | +5,539 | — | — |
| Jun 11, 2026 | Alan Sebulsky Director | Open-market purchase | +12,500 | $20.00 | $250,000 |
| Jun 11, 2026 | Alexis Borisy Director | Derivative conversion | +105,414 | — | — |
| Jun 11, 2026 | Deerfield Mgmt HIF, L.P. 10% owner, Possible Member of 10% Group | Derivative conversion | +122,990 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Parabilis Medicines Inc.
Who is the CEO of Parabilis Medicines Inc.?
Mathai Mammen has been Parabilis Medicines Inc.'s President & CEO since June 2026.
How many directors are on Parabilis Medicines Inc.'s board?
Parabilis Medicines Inc.'s board has 11 directors: Alan Sebulsky, Alexis Borisy, Barbara Weber, Craig Tendler, Edward M. Fitzgerald, Jake Simson, Krishna Yeshwant, Mathai Mammen, Peter Kolchinsky, Rajeev M. Shah and 1 other.
Are Parabilis Medicines Inc. insiders buying or selling shares?
Over the last 12 months, Parabilis Medicines Inc. insiders bought $441.4 million of shares in 14 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="parabilis-medicines-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.